Natural Product Sciences

The Korean Society of Pharmacognosy (한국생약학회)
권호 표지

Anti-hyperlipidemic Effect of Insamsansa-eum in Mice

  • Published : 2008.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Hypolipidemic effect of Insamsansa-eum (ISE, Ren-Shen-Shan-Zah-Yin in Chinese) consisted of Red ginseng (RG; the steamed root of Panax ginseng C.A. Meyer) and Crataegii fructus (CF, the fruit of Crataegus pinnatifida BGE) is used frequently in China and Korea as a herbal medicine to treat arteriosclerosis, was investigated. Treatment of ISE significantly reduced blood triglyceride (TG) and total cholesterol (TC) levels in Triton WR-1339-induced hyperlipidemic mice and serum TG levels in corn oil-induced hypertriglyceridemic mice. ISE significantly lowered the high blood TG and TC levels as well as body and epididymal mass weights in hyperlipidemic mice induced by long-term feeding of a high-fat diet and increased blood HDL cholesterol level. ISE and its ingredients, RG and CF, inhibited pancreatic lipase and HMG-CoA reductase activities. Of its ingredients, RG reduced the blood TC level and HMG-CoA reductase activity more than CF. CF reduced blood TG level and pancreatic lipase activity more than RG. These finding suggest that the antihyperlipidemic effect of ISE may be due to synergistic inhibition of HMG-CoA reductase and pancreatic lipase by RG and CF, and that ISE may be effective hypolipidemic agents.

Keywords

References

  1. Allain, C.C., Poon, L.S., Chan, C.S.G., Richmond, W., and Fu, P.C., Enzymatic determination of total serum cholesterol. Clin. Chem. 20, 470-475 (1974)
  2. Bae, E.A., Han, M.J., Choo, M.K., Park, S.Y., and Kim, D.H., Metabolism of 20(S)- and 20(R)-ginsenoside Rg3 by human intestinal bacteria and its relation to in vitro biological activities. Biol. Pharm. Bull. 25, 58-63 (2002) https://doi.org/10.1248/bpb.25.58
  3. Ballinger, A., Orlistat in the treatment of obesity. Expert. Opin. Pharmacother. 1, 841-847 (2000) https://doi.org/10.1517/14656566.1.4.841
  4. Birari, R.B. and Bhutani, K.K., Pancreatic lipase inhibitors from natural sources: unexplored potential. Drug Discovery Today 12, 879-889 (2007) https://doi.org/10.1016/j.drudis.2007.07.024
  5. Carey, M.C., Small, D.M., and Bliss, C.M., Lipid digestion and absorption. Annu. Rev. Physiol. 45, 651-677 (1983) https://doi.org/10.1146/annurev.ph.45.030183.003251
  6. Chang, W.T., Dao, J., and Shao, Z.H., Hawthorn: potential roles in cardiovascular disease. Am. J. Chin. Med. 33, 1-10 (2005) https://doi.org/10.1142/S0192415X05002606
  7. Davidson, M.H., Ezetimibe: a novel option for lowering cholesterol. Expert. Rev. Cardiovasc. Ther. 1, 11-21 (2003) https://doi.org/10.1586/14779072.1.1.11
  8. Duhault, J., Boulanger, M., Beregi, L., Sicot, N., and Bouvier, F., 780 SE: a new type of hypolipemic agent. Atherosclerosis 23, 63-72 (1976) https://doi.org/10.1016/0021-9150(76)90118-0
  9. Edwards, P.A., Lemongello, D., and Fogelman, A.M., Improved methods for the solubilization and assay of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase. J. Lipid Res. 20, 40-46 (1979)
  10. Edwards, P.A., Lemongello, D., and Kane, J., Properties of purified rat hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase and regulation of enzyme activity. J. Biol. Chem. 255, 3715-3725 (1980)
  11. Endo, A., The discovery and development of HMG-CoA reductase inhibitors. J. Lipid Res. 33, 1569-1582 (1992)
  12. Espenshade, P.J. and Hughes, A.L., Regulation of sterol synthesis in eukaryotes. Annu. Rev. Genet. 41, 401-427 (2007) https://doi.org/10.1146/annurev.genet.41.110306.130315
  13. Goldstein, J.L., Schrott, H., Hazzard, E., Bierman, E., and Motuski, A., Hyperlipidemia in coronary heart disease. I. Lipid levels in 500 survivors of myocardial infarction. J. Clin. Invest. 52, 1544-1568 (1973) https://doi.org/10.1172/JCI107332
  14. Heber, D., Herbs and atherosclerosis. Curr. Atheroscler. Rep. 3, 93-96 (2001) https://doi.org/10.1007/s11883-001-0016-9
  15. Heller, R.A. and Shrewsburg, M.A., 3-Hydroxy-3-methylglutaryl coenzyme A reductase from rat liver. Its purification, properties, and immunochemical studies. J. Biol. Chem. 251, 3815-3822 (1976)
  16. Ia Cour, B., Molgaard, P., and Yi, Z., Traditional Chinese medicine in treatment of hyperlipidaemia. J. Ethnopharmacol. 46, 125-129 (1995) https://doi.org/10.1016/0378-8741(95)01234-5
  17. Inoue, M., Wu, C.Z., Dou, D.Q., Chen, Y.J., and Ogihara, Y., Lipoprotein lipase activation by red ginseng saponins in hyperlipidemia model animals. Phytomedicine 6, 257-265 (1999) https://doi.org/10.1016/S0944-7113(99)80018-X
  18. Kim, H.Y., Jeong da M., Jung, H.J., Jung, Y.J., Yokozawa, T., and Choi, J.S., Hypolipidemic effects of Sophora flavescens and its constituents in poloxamer 407-induced hyperlipidemic and cholesterol-fed rats. Biol. Pharm. Bull. 31, 73-78 (2008) https://doi.org/10.1248/bpb.31.73
  19. Liu, J., Pharmacology of oleanolic acid and ursolic acid. J. Ethnopharmacol. 49, 57-68 (1995) https://doi.org/10.1016/0378-8741(95)90032-2
  20. Meigs, T.E., Roseman, D.S., and Simoni, R.D., Regulation of 3-hydroxy- 3-methylglutaryl-coenzyme A reductase degradation by the nonsterol mevalonate metabolite farnesol in vivo. J. Biol. Chem. 271, 7916- 7922(1996) https://doi.org/10.1074/jbc.271.14.7916
  21. Thomson, A.B., Schoeller, C., Keelan, M., Smith, L., and Clandinin, M.T., Lipid absorption: passing through the unstirred layers, brushborder membrane, and beyond. Can. J. Physiol. Pharmacol. 71, 531- 555 (1993) https://doi.org/10.1139/y93-078
  22. Thompson Coon J.S. and Ernst, E., Herbs for serum cholesterol reduction: a systematic view. J. Fam. Pract. 52, 468-478 (2003)
  23. Trinh, H.T., Han, S.J., Kim, S.W., Lee, Y.C., and Kim, D.H., Bifidus fermentation increases hypolipidemic and hypoglycemic effects of red ginseng. J. Microbiol. Biotechnol. 17, 1127-1133 (2007)
  24. White, L.W. and Rudney, H., Regulation of 3-hydroxy-3-methylglutarate and mevalonate biosynthesis by rat liver homogenates. Effects of fasting, cholesterol feeding, and triton administration. Biochemistry 9, 2725-2731 (1970) https://doi.org/10.1021/bi00815a021
  25. Zhou, L., Zuo, Z., and Chow, MS., Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J. Clin. Pharmacol. 45, 1345-1359 (2005) https://doi.org/10.1177/0091270005282630
  26. Kusama, H., Nishiyama, M., and Ikeda, S., Pharmacological investigation of bezafibrate, a hypolipidemic agent (1). Effects of bezafibrate on normal and experimental hyperlipidemia in rats. Folia Pharmacol. Jpn. 92, 175-180 (1988) https://doi.org/10.1254/fpj.92.175
  27. Sardesai, V.M. and Mannig, J.A., The determination of triglycerides in plasma and tissues. Clin. Chem. 14, 156-158 (1968)